Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Active, not recruiting · NCT04074967 · Registry updated 2025-11-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-11-06 | NCT04074967 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Array BioPharma | 3 |
| Dan Zandberg | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |